Can Mitoquinol Protect Myocardial Energetics in Diabetic Cardiomyopathy?
Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience.
Diabetic cardiomyopathy develops silently, often preceding detectable structural heart disease. Despite preserved ejection fraction, affected myocardium exhibits impaired energy metabolism, diminished diastolic relaxation, and heightened vulnerability to heart failure. This trial examined whether targeting mitochondrial oxidative stress could restore myocardial energetic capacity in patients with type 2 diabetes (T2D).
Research Summary:
Evidence type: Randomised, controlled clinical trial (open-label, blinded endpoint)
Claim strength: Causal (physiological endpoints), positive
Population: 70 adults with type 2 diabetes without established cardiovascular disease
Intervention: Mitoquinol 40 mg/day vs standard care (16 weeks)
Primary outcomes: Myocardial energetics (PCr/ATP ratio), cardiac function (CMR), diastolic function
Observed outcome: Improved cardiac energetics at rest and under stress; improved diastolic function; no change in ejection fraction or perfusion
Causality: Supported for cardiac energetic improvements
Source: Heart (BCS Abstract, 2025)
What you'll learn:
How type 2 diabetes impairs myocardial energetics independently of atherosclerosis or glycaemic control
The role of mitochondrial oxidative stress in reducing the cardiac PCr/ATP ratio and diastolic relaxation
The impact of 16 weeks of Mitoquinol supplementation on myocardial energy reserves and diastolic strain rate
Why improvements in cardiac function occurred without changes in HbA1c—and what this implies for treatment strategy
What is the link between diabetes and cardiovascular dysfunction?
T2D causes cardiac dysfunction through mechanisms distinct from traditional vascular disease. Chronic hyperglycaemia and lipid excess cause structural and functional changes to the myocardium including: fibrosis, lipid deposition, left-ventricle hypertrophy, and oxidative stress.
Chronic oxidative stress in the myocardium impairs mitochondrial efficiency, increasing mtROS production and reducing ATP output. Over time, this energetic deficit compromises myocardial contractility.
Because early diabetic cardiomyopathy lacks overt structural abnormalities, it frequently escapes clinical detection. The phosphocreatine-to-ATP (PCr/ATP) ratio, measured by cardiac magnetic resonance spectroscopy, provides a sensitive index of myocardial energetic health and is consistently depressed in T2D patients.
How are mitochondrial bioenergetics implicated in diabetic cardiomyopathy?
The heart has the highest ATP demand of any organ and relies almost exclusively on mitochondrial oxidative phosphorylation to sustain contractile function. In the diabetic myocardium, oxidative damage disrupts electron transport chain efficiency and impairs the phosphocreatine shuttle that buffers ATP availability, particularly during periods of increased workload.
A reduced PCr/ATP ratio at rest reflects chronic energetic insufficiency, while a further reduction under stress indicates limited metabolic reserve. Diastolic dysfunction is the earliest functional manifestation of this deficit, as myocardial relaxation is tightly coupled to ATP availability.
How might Mitoquinol improve mitochondrial function in diabetic patients?
Type 2 diabetes is associated with elevated mitochondrial oxidative stress in energy‑demanding tissues such as the myocardium. Excess electron leakage from the respiratory chain promotes superoxide production, impairing oxidative phosphorylation and disrupting ATP and phosphocreatine homeostasis—hallmarks of diabetic cardiomyopathy.
Mitoquinol was specifically developed to target this mitochondrial redox imbalance. Conjugation of a ubiquinone moiety to the lipophilic triphenylphosphonium (TPP⁺) cation enables selective accumulation within mitochondria, driven by the inner mitochondrial membrane potential. Once localised, Mitoquinol scavenges superoxide and limits oxidative disruption of electron transport chain activity.
By preserving electron transport efficiency, Mitoquinol supports ATP synthesis and PCr regeneration, addressing the myocardial energetic deficit at its source rather than through nonspecific systemic antioxidant effects.
Importantly, this mechanism operates independently of glucose metabolism. Mitoquinol does not alter glycaemic control but instead mitigates the mitochondrial oxidative burden imposed by chronic hyperglycaemia—an advantage given the limited impact of glucose‑lowering therapies on cardiac energetic dysfunction.
What was the impact of Mitoquinol on the heart’s energy reserves?
Building on this mechanistic rationale, investigators assessed whether mitochondrial‑targeted antioxidant therapy could improve myocardial energetics in patients with established T2D. In a randomised, placebo‑controlled trial of 70 participants, daily supplementation with 40 mg of Mitoquinol was administered for 16 weeks.
Phosphorus magnetic resonance spectroscopy revealed significant improvements in myocardial high‑energy phosphate metabolism. Resting PCr/ATP increased from 1.58 to 1.78, while stress PCr/ATP rose from 1.25 to 1.46 following supplementation.
These shifts indicate restoration of baseline energetic capacity and enhanced ability to meet increased metabolic demand under stress, suggesting meaningful correction of chronic myocardial energy constraint.
How did improved energetics translate to heart function?
Energetic improvements were accompanied by a significant increase in peak early diastolic strain rate (PEDSR), a sensitive marker of myocardial relaxation. Diastolic dysfunction is the earliest functional consequence of diabetic cardiomyopathy and a key predictor of progression to heart failure.
Observation of functional improvement over a 16‑week period, in patients without established heart failure, suggests the intervention acts early in disease progression and may modify trajectory rather than merely slow late‑stage decline.
What are the practitioner insights for T2D management?
Notably, these cardiac benefits occurred without changes in HbA1c. While standard T2D management prioritises glycaemic control, myocardial dysfunction often progresses independently of circulating glucose levels.
Mitoquinol mesylate may be an attractive adjunct therapy to improve heart health in patients with T2D. By targeting mitochondrial redox balance rather than glucose handling, Mitoquinol addresses a parallel pathophysiological pathway largely untouched by existing therapies. This positions mitochondrial health as a distinct and potentially actionable target in the prevention of diabetic cardiovascular disease.
Read full article:Accelerated biological ageing and cardiovascular disease trajectories: a multistate analysis – PubMed
DOI: 10.1136/heartjnl-2025-BCS.283
